{
    "clinical_study": {
        "@rank": "105720", 
        "acronym": "ALbumin", 
        "arm_group": [
            {
                "arm_group_label": "Human Serum Albumin 20", 
                "arm_group_type": "Experimental", 
                "description": "Human Serum Albumin 20% 100cc intravenously infused over 4~8h"
            }, 
            {
                "arm_group_label": "0.9 % Normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment with same volume of normal saline"
            }
        ], 
        "brief_summary": {
            "textblock": "In this clinical study, the efficacy and safety of ALbumin is to be evaluated for the\n      patients occurred within 12 hours of acute ischemic stroke."
        }, 
        "brief_title": "The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cerebral Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Infarction", 
                "Stroke", 
                "Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "According to the statistics of the cause of death in 2008 by the Statistics Korea, the\n      stroke was accounted for a large proportion of cause of death among adults, as well as\n      higher mortality, severe sequelae. These stroke in acute phase showed neurological\n      deterioration over 50% of the patients after beginning of treatment and the sequelae\n      resulting in that the nervous tissue was not regenerated is regarded as irreversible\n      changes.\n\n      The test group administered 20% albumin based on 1.25g/kg (up to 100g (500ml) over 80kg body\n      weight) to the patients occurred within 12 hours of the onset of symptoms and equal amount\n      of placebo (saline solution (0.9% normal saline)) administered to the control group will be\n      compared to evaluate the efficacy and safety of ALbumin for the patients with acute ischemic\n      stroke."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age less than 75 years old\n\n          -  Patients who can be administered ALbumin within 12hours of onset of acute ischemic\n             stroke\n\n          -  5 \u2264 NIHSS score < 15\n\n          -  Patients who are agreed by guardian or legal representative in case that patients\n             have no ability to join study voluntarily\n\n        Exclusion Criteria:\n\n          -  Medical history of congestive heart failure or patients who are judged congestive\n             heart failure on admission.\n\n          -  Patients with cardiac edema or pulmonary edema.\n\n          -  Medical history of myocardial infarction within the past six months.\n\n          -  Patients who have serious aortic stenosis and mitral valve stenosis.\n\n          -  Signs or symptoms of acute MI on admission (Serum troponin level \u22640.1 ug/L)\n\n          -  Those Who had cardiac surgery.\n\n          -  Onset of cerebral infarction within the past three months.\n\n          -  Before onset of cerebral infarction, patients who were diagnosed as Historical mRS \u2265\n             2.\n\n          -  Patients who received treatment of thrombolysis or who planned for treatment of\n             thrombolysis.\n\n          -  Acute tachyarrhythmia or bradyarrhythmia with hemodynamic instability on admission.\n\n          -  Acute or chronic lung disease requiring supplemental O2 therapy on admission\n\n          -  Severe anemia (Hb < 8.0)\n\n          -  Severe dehydration (defined as decreased skin turgor, dry oral mucous membrane,\n             tachycardia(>100/min), and oliguria)\n\n          -  Fever, defined as core body temperature>37.5 \u2103\n\n          -  Serum creatinine > 2.0 mg/dL\n\n          -  History of allergy to albumin.\n\n          -  Patients who have side effects of albumin (hyperergia to shock, fever, facial\n             flushing,urticarial, algor, lumbodynia)\n\n          -  Pregnancy\n\n          -  Patients who are in life-threatening or stupor coma situation.\n\n          -  Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid\n             hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on\n             admission CT or MRI scan.\n\n          -  Patients who are not the normal, excesses of circulating blood.\n\n          -  Haemolytic anemia, anemia due to blood loss.\n\n          -  Immunodeficiency disease, immunosuppression.\n\n          -  Blood pressure higher than 180/110 mmHg on admission."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684462", 
            "org_study_id": "AL_IIT_01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Human Serum Albumin 20", 
                "description": "Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously  infused over 4~8h, commencing within 12 hours of stroke onset", 
                "intervention_name": "Human Serum Albumin 20", 
                "intervention_type": "Biological", 
                "other_name": "Human Serum Albumin Injection 20% 100ml Greencross"
            }, 
            {
                "arm_group_label": "0.9 % Normal saline", 
                "description": "Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset", 
                "intervention_name": "0.9 % Normal Saline", 
                "intervention_type": "Drug", 
                "other_name": "0.9 % Normal Saline ChoongWae INJ. 100ml"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute Ischemic Stroke", 
            "Albumin"
        ], 
        "lastchanged_date": "November 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggido"
                    }, 
                    "name": "St. Vincent's hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mok-dong", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "158-710"
                    }, 
                    "name": "Ewha Womans University Mokdong Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seocho-Gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "137-701"
                    }, 
                    "name": "Seoul St. Mary's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yeongdeungpo-Gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "150-713"
                    }, 
                    "name": "Yeoudo St. Mary's hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIB Placebo Comparative, Double Blinded, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of ALbumin Therapy in Acute Ischemic Stroke Patients in Korea.", 
        "overall_official": {
            "affiliation": "Seoul St. Mary's Hospital", 
            "last_name": "Kwang Soo Lee, M.D, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comparison of the average change in NIHSS between the control and ALbumin group at screening(-12h~0days) and 14\u00b13days", 
            "measure": "Average change in NIHSS", 
            "safety_issue": "Yes", 
            "time_frame": "at 14\u00b13days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684462"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul St. Mary's Hospital", 
            "investigator_full_name": "Kwang Soo Lee", 
            "investigator_title": "Neurology  Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparison of NIHSS score between the control and ALbumin group at 14\u00b13days", 
                "measure": "NIHSS Score", 
                "safety_issue": "Yes", 
                "time_frame": "at 14\u00b13days"
            }, 
            {
                "description": "Comparison of the proportion of patients with improvement in NIHSS over 4 at 14\u00b13days.", 
                "measure": "Proportion of patients with improvement by NIHSS", 
                "safety_issue": "Yes", 
                "time_frame": "at 14\u00b13days"
            }, 
            {
                "description": "Comparison of the global functional outcome on modified Rankin Scale(mRS) at screening(-12h~0days) and 3 months.", 
                "measure": "modified Rankin Scale(mRS) favorable outcome", 
                "safety_issue": "Yes", 
                "time_frame": "at 3 months"
            }, 
            {
                "description": "Comparison of the volume difference of cerebral infraction defined by diffusion MRI at 4\u00b11days", 
                "measure": "Volume difference on diffusion MRI", 
                "safety_issue": "Yes", 
                "time_frame": "at 4 days\u00b11days"
            }, 
            {
                "description": "Comparison of the proportion of patients who appear to be recurrent new ischemic lesions defined by diffusion MRI", 
                "measure": "Recurrent new ischemic lesions on diffusion MRI", 
                "safety_issue": "Yes", 
                "time_frame": "at 4\u00b11days"
            }
        ], 
        "source": "Seoul St. Mary's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Seoul St. Mary's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}